DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Multikinase inhibitors
Regorafenib
Regorafenib (BAY 73-4506) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. It is currently being studied as a potential treatment option in multiple tumor types.
Multikinase inhibitors - List of case studies
- Drugs
-
5-fluorouracil 5FU A ACE inhibitors ACNS 0222 gadolinium texaphyrin ALIMTA ALLORIL ... Modified FOLFOX-4 Motesanib Moxifloxacine Multikinase inhibitors Muphoran Muscle relaxants Muscoril ...
- Papillary Carcinoma of Thyroid with Multiple and Diffuse Nodular Secondarisms of the Pulmonary Parenchyma
-
that demonstrate activity in PTC with oral angiogenesis/multikinase inhibitors , such as AMG 706 (Sherman, NEJM, 2008) and sorafenib ...